The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.
 
Richard Bryan Bell
Consulting or Advisory Role - Stryker
Speakers' Bureau - Merck
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Prometheus (Inst)
 
Rebekka Duhen
Employment - Agonox (I)
Research Funding - MedImmune; MedImmune (I)
 
Rom S. Leidner
Employment - Agonox (I)
Honoraria - AstraZeneca
Research Funding - Bristol-Myers Squibb; MedImmune (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Brendan D. Curti
Consulting or Advisory Role - Alligator Bioscience; Eisai
Speakers' Bureau - Bristol-Myers Squibb; Prometheus
Research Funding - Bristol-Myers Squibb (Inst); Galectin Therapeutics (Inst); MedImmune (Inst); Prometheus (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MedImmune; Prometheus
 
Carmen Ballesteros-Merino
No Relationships to Disclose
 
Brian Piening
No Relationships to Disclose
 
Brady Bernard
No Relationships to Disclose
 
Joanna Pucilowska
No Relationships to Disclose
 
Carlo Bruno Bifulco
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb (Inst)
 
Bernard A. Fox
Employment - UbiVac; UbiVac (I)
Leadership - UbiVac
Stock and Other Ownership Interests - PrimeVax; UbiVac
Honoraria - Janssen Biotech; Nodality
Consulting or Advisory Role - Bayer; Celldex; Definiens; MedImmune
Research Funding - Bristol-Myers Squibb; DEfiniens; Janssen Biotech; MedImmune (Inst); Perkin Elmer; Viralytics
Patents, Royalties, Other Intellectual Property - Patent around the DPV-001 cancer vaccine. This patent is owned by the Providence Health System and licensed to UbiVac
 
Thomas Duhen
Employment - Agonox
Research Funding - MedImmune; MedImmune (I)
 
William L Redmond
Research Funding - Aeglea Biotherapeutics; Bristol-Myers Squibb; DNAtrix; Galectin Therapeutics; IRX Therapeutics; MedImmune; Merck; Nektar; Shire Human Genetic Therapies; Tesaro
 
Yoshinobu Koguchi
No Relationships to Disclose
 
Allen Cheng
No Relationships to Disclose
 
Ashish A. Patel
No Relationships to Disclose
 
George Morris
No Relationships to Disclose
 
Raina Tamakawa
No Relationships to Disclose
 
Mark W. Schuster
No Relationships to Disclose
 
Walter John Urba
Leadership - Leidos Biomedical Research
Stock and Other Ownership Interests - Pfizer
Honoraria - Bristol-Myers Squibb; Celldex; MedImmune; Newlink Genetics; OncoSec
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Celldex; eTheRNA; GreenPeptide; MedImmune (Inst); Newlink Genetics; OncoSec
Research Funding - Bristol-Myers Squibb (Inst); Galectin Therapeutics (Inst); MedImmune (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Galectin Therapeutics (Inst); MedImmune (Inst)
Travel, Accommodations, Expenses - AgonOx; Bristol-Myers Squibb; eTheRNA; Leidos Biomedical Research; MedImmune
 
Andrew D. Weinberg
Employment - Agonox
Stock and Other Ownership Interests - Agonox
Research Funding - MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - I am on patents relating to using OX40 agonists in cancer patients
Travel, Accommodations, Expenses - Agonox